We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Research and Markets Announces the Addition of Proteomics: Current State and Future Directions


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Research and Markets Announces the Addition of Proteomics: Current State and Future Directions"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

Research and Markets has announced the addition of Proteomics: Current State and Future Directions to their offering.

Proteomics: Current State and Future Directions is a report that delivers an up-to-the-minute assessment of the state of proteomics and its applications in drug and biomarker discovery. The report provides insight into:

- Strengths and weaknesses of the leading technologies for protein separation, detection, and quantification - with an emphasis on high-throughput approaches

- The fundamental challenge posed by the vast dynamic range among protein concentrations, and the potential solutions in development and entering the market

- Recent applications of proteomics to discover biomarkers for preeclampsia, and for neonatal ureteropelvic junction, and to differentiate between diagnosis of ALS and Parkinson’s disease

- Technologies such as mass spectrometry, antibody-bearing chips, and solution array multiplexing to address the challenge of detecting low-abundance proteins

- The most significant research initiatives and recent product introductions, company profiles, and the major deals and M&As that are shaping the proteomics landscape

A quantitative survey (N=81) of individuals involved with proteomics at biopharmaceutical and diagnostic firms, vendors of equipment and services, and academic research departments sheds light on current practices and future directions in the use of proteomics in pharmaceutical R&D. Among the highlights:

- 69% of respondents are using proteomics to discover novel biomarkers

- Antibody/protein arrays and solution arrays will begin to gain ground as detection platforms over the next 3 years

Expert interviews with 3 authorities on proteomics provide penetrating commercial and scientific insights into state of proteomics.

Roger Brent, PhD (president and research director of the Molecular Sciences Institute in Berkeley, CA, and cofounder of Aptanomics SA) examines the commercial opportunity and economic realities of using proteomics in the clinic.

Gilbert S. Omenn, MD, PhD (co-director of the Human Proteome Organization’s Plasma Proteome Project and professor/director of the Center for Computational Medicine and Biology at the University of Michigan) discusses solutions for overcoming the problem of high protein concentration in plasma samples.

James R. Heath, PhD (professor of chemistry at California Institute of Technology) shares his vision of dynamic, multiparameter network models, driven by nanotechnology, that describe how biological systems change over time.

Section 1
Introduction: The Current State of Proteomics Technology

Section 2
A Brief History of Proteomics Technology

Section 3
General Overview of Proteomics Research Challenges

Section 4
Current Technologies

Section 5
Research Comparing Quantification Methods

Section 6
Technical Challenges

Section 7
Selected Research Methods Reports

Section 8
Selected Product Introductions

Section 9
Selected Deals and Mergers

Section 10
Expert Interviews: Current State and Future Directions

Section 11
Selected Company Profiles

Appendix
2006 Proteomics Survey
References

Companies Mentioned:

Selected Company Profiles: - BiaCore, BioRad, Invitrogen, Luminex, Thermo Electron

Selected Deals and Mergers:

Combi Matrix/Biodesign Institute, Caprion/ICOS, Affibody/Agilent, PerkinElmer/Agilix, Applied Biosystems/Invitrogen, PerkinElmer/Luminex

Advertisement